Evidence map›Paper›PMID 38601632›Full record

ArticleHeliyon2024

Evaluation of curcumin-based ophthalmic nano-emulsion on atropine-induced dry eye in mice.

Mahsa Hadipour Jahromy, Mahnaz Qomi, Simin Fazelipour, Nafiseh Sami, Farzaneh Faali, Mehrnaz Karimi, Farhad Adhami Moghadam

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mahsa Hadipour JahromyHerbal Pharmacology Research Center, School of Medicine, Dept of Pharmacology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Mahnaz QomiActive Pharmaceutical Ingredients Research Center (APIRC), Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Simin FazelipourSchool of Medicine, Dept of Histology & Anatomy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Nafiseh SamiSchool of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Farzaneh FaaliSchool of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Mehrnaz KarimiDepartment of Nanotechnology, School of Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Farhad Adhami MoghadamSchool of Medicine, Dept of Ophthalmology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Islamic Azad University Medical Branch of Tehran · IRIslamic Azad University, Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: One of the most efficient treatments for dry eye syndrome (DES) is to use nanocarriers as a potential delivery system. We aim to evaluate curcumin in a nano emulsion formulation. Methods: A new formulation containing 5.5% curcuminoid was used. DLS, Zeta potential, TEM, and HPLC tests were performed to determine the size and morphology. First, 30 mice were selected as atropine-induced dry eye models. Next, 25 mice in 5 groups were treated with the nano emulsion at different doses, and corneal tissues were separated for evaluation. Results: The DLS test results were indicative of the particles' stability. Nano curcumin appeared to be thoroughly effective in all groups, with the highest dose showing the most similarity to the healthy control group. Conclusions: Curcumin-based nano emulsion eye drop is a promising candidate for DES management. However, further investigation is required to evaluate the possible risks in humans.

Indexed as

Atropine-induced dry eyeMiceNanocurcuminNano emulsion

Identifiers

PMID38601632
PMCPMC11004198
OpenAlexW4393857803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.